Free Trial
$100 Off. Every Year. Lock In MarketBeat All Access at $149
Claim the Rate Lock
Claim MarketBeat All Access Sale Promotion

Canaccord Genuity Group's Rating of Viking Therapeutics on 10/20/2026

On October 20, 2026, Canaccord Genuity Group updated its outlook on Viking Therapeutics (NASDAQ:VKTX) with the action "Lower Price Target", setting a price target of $106.00. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from Canaccord Genuity Group Inc.

DateCompanyAction
10/21/2026
Netflix, Inc. stock logo
NFLX
Netflix
Set Price Target
10/21/2026
Afentra plc stock logo
AET
Afentra
Reiterated Rating
10/20/2026
Braze, Inc. stock logo
BRZE
Braze
Set Price Target
10/20/2026
GB Group plc stock logo
GBG
GB Group
Reiterated Rating
10/20/2026
Wickes Group plc stock logo
WIX
Wickes Group
Reiterated Rating
10/19/2026
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
Initiated Coverage
More Ratings From Canaccord Genuity Group Inc.